Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. (NASDAQ Capital Market: ALDX) is a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases. The company's website is located at https://ir.aldeyra.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aldeyra Therapeutics, Inc. does
In the company’s own words
Aldeyra Therapeutics, Inc. (NASDAQ Capital Market: ALDX) is a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases. The company's website is located at https://ir.aldeyra.com.
Aldeyra's core approach focuses on developing pharmaceuticals that modulate protein systems rather than directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways simultaneously while minimizing toxicity. The company's primary platform technology centers on reactive aldehyde species, or RASP, modulators—novel small molecules designed to bind and allow for the degradation and depletion of RASP, which are elevated in various inflammatory and immune-mediated diseases.
The company's development pipeline includes several late-stage product candidates. Reproxalap, a topically administered RASP modulator, represents the company's most advanced program and is in late-stage development for the treatment of dry eye disease and allergic conjunctivitis. The compound has been studied in more than 2,500 patients across multiple clinical trials and has demonstrated consistent statistically significant activity with a favorable safety profile. ADX-2191, a novel intravitreal formulation of methotrexate, is being developed for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company is also advancing next-generation RASP modulators ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases, respectively.
In October 2023, Aldeyra entered into an exclusive option agreement with AbbVie Inc., granting AbbVie an exclusive option to obtain a co-exclusive license in the United States and an exclusive license outside the United States for reproxalap, along with rights of first negotiation and data review in related fields. Under this agreement, AbbVie has the potential to pay up to approximately $400 million in upfront and milestone payments, with profit-sharing arrangements in the United States and tiered royalties internationally upon exercise of the option.
Aldeyra has no approved products for sale and has primarily funded operations through equity and debt financing. The company has devoted substantially all resources to preclinical and clinical development of its product candidates and intends to commercialize approved products either directly or through strategic partnerships.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1341235
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aldeyra Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aldeyra Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aldeyra Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aldeyra Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aldeyra Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”